These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 804510)

  • 21. Complement activation in semisolid media: insolubilization of alternative pathway convertases in agar gels with C3 nephritic factor-containing sera.
    Arnaout MA; Davis AE; Rosen RS; Alper CA
    J Immunol; 1977 Oct; 119(4):1316-20. PubMed ID: 894039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A properdin system intermediate formed by zymosan and serum at 0 degrees C.
    Yukiyama Y; Lew FT; Waks HS; Osler AG
    J Immunol; 1976 Jan; 116(1):188-93. PubMed ID: 812914
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
    Brown EJ; Ramsey J; Hammer CH; Frank MM
    J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of TraT protein, an anticomplementary protein produced in Escherichia coli by R100 factor, in serum resistance.
    Pramoonjago P; Kaneko M; Kinoshita T; Ohtsubo E; Takeda J; Hong KS; Inagi R; Inoue K
    J Immunol; 1992 Feb; 148(3):827-36. PubMed ID: 1730875
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence for the presence of components of the alternative (properdin) pathway of complement activation in respiratory secretions.
    Robertson J; Caldwell JR; Castle JR; Waldman RH
    J Immunol; 1976 Sep; 117(3):900-3. PubMed ID: 956659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Restoration by purified C3b inactivator of complement-mediated function in vivo in a patient with C3b inactivator deficiency.
    Ziegler JB; Alper CA; Rosen RS; Lachmann PJ; Sherington L
    J Clin Invest; 1975 Mar; 55(3):668-72. PubMed ID: 1117072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activation of the alternative pathway of complement in childhood acute lymphoblastic leukemia.
    Kalwinsky DK; Urmson JR; Stitzel AE; Spitzer RE
    J Lab Clin Med; 1976 Nov; 88(5):745-56. PubMed ID: 1068203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of antibody and complement in the immune clearance and destruction of erythrocytes. II. Molecular nature of IgG and IgM complement-fixing sites and effects of their interaction with serum.
    Schreiber AD; Frank MM
    J Clin Invest; 1972 Mar; 51(3):583-9. PubMed ID: 4622104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypocomplementemia of membranoproliferative nephritis. Dependence of the nephritic factor reaction on properdin factor B.
    Ruley EJ; Forristal J; Davis NC; Andres C; West CD
    J Clin Invest; 1973 Apr; 52(4):896-904. PubMed ID: 4693654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The interaction of glycoprotein C of herpes simplex virus types 1 and 2 with the alternative complement pathway.
    Hung SL; Peng C; Kostavasili I; Friedman HM; Lambris JD; Eisenberg RJ; Cohen GH
    Virology; 1994 Sep; 203(2):299-312. PubMed ID: 8053154
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Formation of the C3-cleaving properdin enzyme on zymosan. Demonstration that factor D is replaceable by proteolytic enzymes.
    Brade V; Nicholson A; Bitter-Suermann D; Hadding U
    J Immunol; 1974 Dec; 113(6):1735-43. PubMed ID: 4279261
    [No Abstract]   [Full Text] [Related]  

  • 32. Complete absence of the third component of complement in man.
    Ballow M; Shira JE; Harden L; Yang SY; Day NK
    J Clin Invest; 1975 Sep; 56(3):703-10. PubMed ID: 1159084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of factor B and C3 in guinea pig serum by zymosan or by activated properdin depends on the presence of factor D.
    Brade V; Bentley C; Kossorotow A; Bitter-Suermann D
    Monogr Allergy; 1977; 12():83-5. PubMed ID: 917024
    [No Abstract]   [Full Text] [Related]  

  • 34. Nonimmunologic complement activation in normal human serum induced by radiographic contrast media.
    Kolb WP; Lang JH; Lasser EC
    J Immunol; 1978 Oct; 121(4):1232-8. PubMed ID: 100552
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Studies of the alternate pathway in chelated serum.
    Forsgren A; Mclean RH; Michael AF; Quie PG
    J Lab Clin Med; 1975 Jun; 85(6):904-12. PubMed ID: 805816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Initiation of C3 cleavage in the alternative complement pathway.
    Fearon DT; Austen KF
    J Immunol; 1975 Nov; 115(5):1357-61. PubMed ID: 809512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complement fixation by solid phase immune complexes. Reduced capacity in SLE sera.
    Baatrup G; Jonsson H; Sjöholm A; Sturfelt G; Svehag SE
    J Clin Lab Immunol; 1988 Jun; 26(2):73-9. PubMed ID: 3264027
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Purification of a human serum protein ("factor E") which enhances cobra venom factor-induced indirect lysis. Identification with the fifth component of complement.
    Lynen R; Vogt W; Schmidt G; Dieminger L
    Z Immunitatsforsch Exp Klin Immunol; 1976 Apr; 151(2):105-16. PubMed ID: 134530
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanism of complement inactivation by glycoprotein C of herpes simplex virus.
    Kostavasili I; Sahu A; Friedman HM; Eisenberg RJ; Cohen GH; Lambris JD
    J Immunol; 1997 Feb; 158(4):1763-71. PubMed ID: 9029114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An alternate complement pathway: C-3 cleaving activity, not due to C4,2a, on endotoxic lipopolysaccharide after treatment with guinea pig serum; relation to properdin.
    Marcus RL; Shin HS; Mayer MM
    Proc Natl Acad Sci U S A; 1971 Jun; 68(6):1351-4. PubMed ID: 5288385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.